Jasper Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Jasper Therapeutics

07/11/2024 14:38

* Jasper Therapeutics Inc  JSPR.OQ  reported a quarterly
adjusted
loss of $1.24​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.60.  The mean expectation of nine analysts
for the quarter was for a loss of $1.07 per share. Wall Street
expected results to range from $-1.15 to -98 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Jasper Therapeutics Inc's reported EPS for the quarter was
a
loss of $1.24​.
    * The company reported a quarterly loss of $18.64 million.
    * Jasper Therapeutics Inc shares had risen by 26.0% this
quarter and gained 200.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Jasper
Therapeutics Inc is 70.00 
This summary was machine generated from LSEG data November 7 at
02:38 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.07          -1.24          Missed
 Jun. 30 2024      -1.09          -0.97          Beat
 Mar. 31 2024      -1.22                         
 Dec. 31 2023      -1.61